Compare RPD & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPD | ABUS |
|---|---|---|
| Founded | 2000 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 780.5M | 888.5M |
| IPO Year | 2015 | 2008 |
| Metric | RPD | ABUS |
|---|---|---|
| Price | $6.23 | $4.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 21 | 1 |
| Target Price | ★ $16.15 | $5.00 |
| AVG Volume (30 Days) | ★ 1.9M | 1.8M |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.64 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $685,083,000.00 | $6,171,000.00 |
| Revenue This Year | N/A | $125.30 |
| Revenue Next Year | $0.93 | N/A |
| P/E Ratio | $17.42 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.92 | $2.71 |
| 52 Week High | $30.95 | $5.10 |
| Indicator | RPD | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 15.03 | 60.77 |
| Support Level | N/A | $4.22 |
| Resistance Level | $19.70 | $4.69 |
| Average True Range (ATR) | 0.58 | 0.24 |
| MACD | -0.16 | 0.07 |
| Stochastic Oscillator | 5.33 | 88.32 |
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.